Health
Pfizer/BioNTech COVID-19 vaccine continues to show strong effect in early-stage study – Seeking Alpha
Data from an ongoing Phase 1/2 clinical trial evaluating three dose levels of Pfizer (NYSE:PFE) and collaboration partner BioNTech SE’s (NASDAQ:BNTX) COVID-19 vaccine candidate BNT162b1 in healthy volunteers showed an acceptable safety profile and dose-depend…
Data from an ongoing Phase 1/2 clinical trial evaluating three dose levels of Pfizer (NYSE:PFE) and collaboration partner BioNTech SE’s (NASDAQ:BNTX) COVID-19 vaccine candidate BNT162b1 in healthy volunteers showed an acceptable safety profile and dose-dependent increases in glycoprotein receptor-binding domain (RBD)-binding IgG concentrations and SARS-CoV-2 neutralizing antibody titers. The data, just published in the journal Nature, was generated on the first two dose levels, 10 µg and 30 µg. …
-
General11 hours agoAustralian celebrity chef Peter Russell-Clarke dies aged 89
-
Noosa News20 hours agoRainbow Beach surfer’s untold 7/7 story
-
Noosa News10 hours agoWoman airlifted to Brisbane hospital after big cat mauling at south-east Queensland zoo near Toowoomba
-
Noosa News10 hours agoUnvaccinated horse dies from Hendra virus as Queensland records first case in three years